ライフサイエンスコーパス: phentermine

1 f 25 h after intake of a single oral dose of phentermine.

2 te suppressants or among those who took only phentermine.

3 .9 to 87.1) with the use of fenfluramine and phentermine.

4 , and 1 received tirzepatide) and 4 received phentermine.

5 5 mg plus topiramate 46.0 mg, and 73 (7%) to phentermine 15.0 mg plus topiramate 92.0 mg had depressi

6 .5 mg plus topiramate 46.0 mg, or once-daily phentermine 15.0 mg plus topiramate 92.0 mg in a 2:1:2 r

7 ntermine 7.5 mg plus topiramate 46.0 mg, and phentermine 15.0 mg plus topiramate 92.0 mg, respectivel

8 ntermine 7.5 mg plus topiramate 46.0 mg, and phentermine 15.0 mg plus topiramate 92.0 mg, respectivel

9 e 7.5 mg plus topiramate 46.0 mg, and 995 to phentermine 15.0 mg plus topiramate 92.0 mg; 979, 488, a

10 d 687 (70%; 9.0, 7.3 to 11.1; p<0.0001) with phentermine 15.0 mg plus topiramate 92.0 mg; for >/=10%

11 lus placebo (BT + P, n = 38) or BT plus AOM (phentermine = 15.0 mg d(-1), n = 38).

12 ugs in combination (fenfluramine 1 mg/kg and phentermine 2 mg/kg) amplified the effects of each, incr

13 Phentermine (2 mg/kg, i.p.), on the other hand, signific

14 randomly assigned treatment [placebo, 7.5 mg phentermine/46 mg controlled-release topiramate (7.5/46)

15 ratio 6.3, 95% CI 4.9 to 8.0; p<0.0001) with phentermine 7.5 mg plus topiramate 46.0 mg, and 687 (70%

16 4%) patients assigned to placebo, 19 (4%) to phentermine 7.5 mg plus topiramate 46.0 mg, and 73 (7%)

17 tients, 994 were assigned to placebo, 498 to phentermine 7.5 mg plus topiramate 46.0 mg, and 995 to p

18 0.0001) in the patients assigned to placebo, phentermine 7.5 mg plus topiramate 46.0 mg, and phenterm

19 207 [21%] in the groups assigned to placebo, phentermine 7.5 mg plus topiramate 46.0 mg, and phenterm

20 or abdominal obesity) to placebo, once-daily phentermine 7.5 mg plus topiramate 46.0 mg, or once-dail

21 rolled-release topiramate (7.5/46), or 15 mg phentermine/92 mg controlled-release topiramate (15/92)]

22 like peptide 1 (GLP-1) receptor agonist, and phentermine, a psychostimulant structurally related to a

23 nterval, 0 to 15.4) and among those who took phentermine alone (95 percent confidence interval, 0 to

24 r chronic administration of fenfluramine and phentermine, alone or in combination, on brain dopamine

25 ned 1163 patients who had taken fenfluramine-phentermine and 672 control patients who had not taken t

26 (based on moderate certainty evidence), and phentermine and diethylpropion (based on low certainty e

27 A recent meta-analysis of phentermine and diethylpropion reported pooled mean diff

28 Coadministration of phentermine and fenfluramine (phen/fen) effectively trea

29 en the length of treatment with fenfluramine-phentermine and the prevalence of valvular abnormalities

30 erapy for adolescents with obesity, top-dose phentermine and topiramate as adjunct to lifestyle couns

31 The combination of phentermine and topiramate caused significant weight los

32 placebo-controlled trial of extended-release phentermine and topiramate in 24 patients to validate as

33 At 5 years, top-dose phentermine and topiramate was projected to be the prefe

34 d calorie intake; weight loss in response to phentermine and topiramate was significantly associated

35 id-dose phentermine and topiramate, top-dose phentermine and topiramate, or semaglutide over 13 month

36 id-dose phentermine and topiramate, top-dose phentermine and topiramate, or semaglutide.

37 lone and as adjunct to liraglutide, mid-dose phentermine and topiramate, top-dose phentermine and top

38 g alone and adjunct to liraglutide, mid-dose phentermine and topiramate, top-dose phentermine and top

39 The combination of phentermine and topiramate, with office-based lifestyle

40 ht loss of lifestyle counseling and top-dose phentermine and topiramate.

41 llion per QALY gained compared with top-dose phentermine and topiramate.

42 o 102.2) with the use of dexfenfluramine and phentermine, and 26.3 (7.9 to 87.1) with the use of fenf

43 Up-to-date meta-analyses of sibutramine, phentermine, and diethylpropion were identified.

44 e, 3,4-methylenedioxymethamphetamine (MDMA), phentermine, and mephedrone) in one method using their c

45 lesser-known medications such as olanzapine, phentermine, and ranibizumab.

46 ng lesser-known medications like olanzapine, phentermine, and ranibizumab.

47 phetamine, methamphetamine, amphetamine, and phentermine, as well as a non-amphetamine releaser, 4-be

48 with Wegovy at 636.3, Zepbound at 468.9, and phentermine at 301.8.

49 The combination of liraglutide and phentermine, at 100 mug/kg/day and 10 mg/kg/day, respect

50 % CI, 0.6% to 14.8%]) receiving fenfluramine-phentermine developed valvular heart disease.

51 Obese patients who took fenfluramine and phentermine, dexfenfluramine alone, or dexfenfluramine a

52 ase (ER), naltrexone-bupropion ER, orlistat, phentermine, diethylpropion, and Gelesis100 oral superab

53 ns in the United States for fenfluramine and phentermine exceeded 18 million.

54 when the off-label use of fenfluramine plus phentermine (fen-phen) and the approval of dexfenflurami

55 between the clinical failure of fenfluramine-phentermine (fen-phen) and the subsequent research on th

56 valvulopathy associated with treatment with phentermine, fenfluramine, and dexfenfluramine is now be

57 estigation sought to determine the effect of phentermine-fenfluramine (phen-fen) on the prevalence of

58 th the appetite-suppressant drugs, including phentermine-fenfluramine.

59 ence interval [CI], 1.32-3.59), 13.7% in the phentermine/fenfluramine group (RR, 3.34; 95% CI, 2.09-5

60 (10.4) months (range, 1.4-63 months) in the phentermine/fenfluramine group, while the untreated grou

61 ata indicate that use of dexfenfluramine and phentermine/fenfluramine is associated with an increase

62 ] had increases; P<.001 vs controls); and 15 phentermine/fenfluramine patients (4.5% all decreases; P

63 7.5 months (range, 13-26 months) and for 340 phentermine/fenfluramine patients was 18.7 months (range

64 atment were uncommon (dexfenfluramine, 2.3%; phentermine/fenfluramine, 2.4%, and untreated, 3.3%, whe

65 d untreated subjects (dexfenfluramine, 9.0%; phentermine/fenfluramine, 4.0%; and untreated, 8.4%); an

66 e (479 and 455 had taken dexfenfluramine and phentermine/fenfluramine, respectively, continuously for

67 after discontinuation of dexfenfluramine and phentermine/fenfluramine.

68 The negative control drugs were phentermine, fluoxetine, its metabolite norfluoxetine, a

69 uramine and phentermine, or fenfluramine and phentermine for various periods.

70 terest in combination use of liraglutide and phentermine for weight loss; however, both drugs have be

71 exfenfluramine alone, or dexfenfluramine and phentermine had a significantly higher prevalence of car

72 By February 2024, phentermine had approximately 0.74 million monthly presc

73 compounds diethylpropion, fenfluramine, and phentermine had no effect on K(ATP) channel activity in

74 fluramine, usually given in combination with phentermine, has been reported to be associated with car

75 Fenfluramine and phentermine have been individually approved as anorectic

76 pressants fenfluramine, dexfenfluramine, and phentermine have been used alone or in combination as an

77 Topiramate (Topamax) and phentermine have long been approved in the United States

78 te and the antiobesity medications orlistat, phentermine hydrochloride, and sibutramine hydrochloride

79 f the appetite suppressants fenfluramine and phentermine is associated with an increased risk of card

80 codeine, heroine, methamphetamine, morphine, phentermine, L-phenylepherine, proglitazone, and rosigli

81 ese mice, the combination of liraglutide and phentermine may reduce body weight but only induce modes

82 n dexfenfluramine alone, dexfenfluramine and phentermine, or fenfluramine and phentermine for various

83 ropion, sibutramine, fenfluramine, mazindol, phentermine, or orlistat A third cohort included patient

84 ssed the efficacy and safety of two doses of phentermine plus topiramate controlled-release combinati

85 and lorcaserin to 9% for top-dose (15/92 mg) phentermine plus topiramate-extended release at 1 year.

86 3% for orlistat, and 67% to 70% for top-dose phentermine plus topiramate-extended release.

87 ormalities in patients who took fenfluramine-phentermine primarily involve those who had taken these

88 Sibutramine, orlistat, phentermine, probably diethylpropion, bupropion, probabl

89 Phentermine's dropped from 86.3% and 85.1% to 50.8% and

90 Phentermine, semaglutide (Wegovy; Novo Nordisk), liraglu

91 These cases arouse concern that fenfluramine-phentermine therapy may be associated with valvular hear

92 Candidates for fenfluramine-phentermine therapy should be informed about serious pot

93 tion between these features and fenfluramine-phentermine therapy.

94 months after the initiation of fenfluramine-phentermine therapy.

95 received fenfluramine, and 862 who received phentermine to assess the risk of a subsequent clinical

96 5% weight loss vs 75% of participants taking phentermine-topiramate (odds ratio [OR], 9.22; 95% credi

97 Phentermine-topiramate and liraglutide were associated w

98 Centrally acting drugs, such as phentermine-topiramate and naltrexone-bupropion, regulat

99 utide cost more and were less effective than phentermine-topiramate and semaglutide, respectively.

100 dering them not cost-effective compared with phentermine-topiramate at the willingness-to-pay thresho

101 and gastric bypass were more effective than phentermine-topiramate but were also more costly, render

102 e of semaglutide 2.4 mg, liraglutide 3.0 mg, phentermine-topiramate ER, and naltrexone-bupropion ER (

103 nts: semaglutide 2.4 mg, liraglutide 3.0 mg, phentermine-topiramate extended-release (ER), naltrexone

104 Phentermine-topiramate seems to have the highest weight

105 or adolescents with severe obesity, we found phentermine-topiramate to be a cost-effective treatment

106 rugs orlistat, liraglutide, semaglutide, and phentermine-topiramate vs no treatment.

107 linical trials [RCTs]; 16 964 participants), phentermine-topiramate was associated with 8.0% greater

108 drugs currently approved for pediatric use, phentermine-topiramate was the most cost-effective with

109 lucagon-like peptide 1 receptor agonists and phentermine-topiramate).

110 and liraglutide), bupropion-naltrexone, and phentermine-topiramate).

111 weight loss compared with placebo at 1 year-phentermine-topiramate, 8.8 kg (95% CrI, -10.20 to -7.42

112 orlistat, lorcaserin, naltrexone-bupropion, phentermine-topiramate, and liraglutide, compared with p

113 weight loss medications, including orlistat, phentermine-topiramate, bupropion-naltrexone, or setmela

114 While semaglutide offered more QALYs than phentermine-topiramate, its higher cost resulted in an i

115 the FDA for treatment of obesity (orlistat, phentermine-topiramate, naltrexone-bupropion, and liragl

116 t insulinotropic polypeptide/GLP-1 agonist), phentermine-topiramate, naltrexone-bupropion, and orlist

117 irzepatide (6), naltrexone/bupropion (5) and phentermine/topiramate (2)-enrolling 60,307 patients (32

118 Controlled-release phentermine/topiramate (PHEN/TPM CR), as an adjunct to l

119 and liraglutide; in the USA, lorcaserin and phentermine/topiramate are also available.

120 Liraglutide, naltrexone/bupropion, and phentermine/topiramate are new agents that have been rec

121 Semaglutide and phentermine/topiramate had the largest effects on BMI (e

122 tions, such as liraglutide, semaglutide, and phentermine/topiramate, in combination with lifestyle mo

123 nic weight management (orlistat, lorcaserin, phentermine/topiramate, naltrexone/bupropion, and liragl

124 t 6 months of 3.6 kg (CI, 0.6 to 6.0 kg) for phentermine-treated patients and 3.0 kg (CI, -1.6 to 11.

125 The combination of fenfluramine and phentermine was a widely used obesity treatment before t

126 A pharmacokinetic curve for the incurred phentermine was successfully produced using the describe

127 isease in 24 women treated with fenfluramine-phentermine who had no history of cardiac disease.

128 erin and the extended release combination of phentermine with topiramate have recently gained approva